Stock Analysis
Pell Bio-Med Technology Second Quarter 2024 Earnings: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023)
Pell Bio-Med Technology (TWSE:6949) Second Quarter 2024 Results
Key Financial Results
- Net loss: NT$101.5m (loss narrowed by 17% from 2Q 2023).
- NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Pell Bio-Med Technology shares are up 3.4% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 2 warning signs for Pell Bio-Med Technology you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:6949
Pell Bio-Med Technology
A biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications.